Announcements Trials
Browse Landscape

Phase

Phase 2 54Phase 1 22Phase 3 20Phase 1/2 11Phase EARLY_PHASE1 6Phase 4 4Phase 2/3 2Phase NA 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Breast 2Tumor-Agnostic 1Head & Neck 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1BRCA or HRR+ Mutated Ovarian Cancer Patients 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 10human papillomavirus vaccine, L1 type 16, 18 7olaparib 4niraparib 4Human Papillomavirus Recombinant Vaccine nonavalent 4Vaccines 3Saline Solution 3Papillomavirus Vaccines 3Medroxyprogesterone Acetate 3Carboplatin 3Bevacizumab 3pegylated granulocyte colony-stimulating factor 2liposomal doxorubicin 2fluciclovine F-18 2apatinib 2Sevoflurane 2Propofol 2Paclitaxel 2Aspirin 2semaglutide 1pegfilgrastim 1pazopanib 1palbociclib 1lenvatinib 1halofantrine 1ganirelix 1gadofosveset trisodium 1fosaprepitant 1follicle stimulating hormone, human, with HCG C-terminal peptide 1ferrous gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × olaparib × Gynecologic × Clear all
NCT06121401 2025-09-17

IOLANTHE

Mario Negri Institute for Pharmacological Research

Phase 4 Active not recruiting
190 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT04330040 2025-03-10

SOLI

AstraZeneca

Phase 4 Completed
202 enrolled 15 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05949424 2023-11-29

OPTI-DOSE

University Medical Center Groningen

Phase 4 Unknown
30 enrolled
BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT02476968 2022-09-10

ORZORA

AstraZeneca

Phase 4 Completed
181 enrolled 24 charts
Gynecologic

BRCA or HRR+ Mutated Ovarian Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡